Education
About Us
Working with TipRanks
Follow Us
Iteos Therapeutics, Inc. (ITOS)
:ITOS
ITOS Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
iTeos Therapeutics News
ITOS FAQ
What was Iteos Therapeutics, Inc.’s price range in the past 12 months?
Currently, no data Available
What is Iteos Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Iteos Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Iteos Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Iteos Therapeutics, Inc. overvalued?
According to Wall Street analysts Iteos Therapeutics, Inc.’s price is currently Undervalued.
Does Iteos Therapeutics, Inc. pay dividends?
Iteos Therapeutics, Inc. does not currently pay dividends.
What is Iteos Therapeutics, Inc.’s EPS estimate?
Iteos Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Iteos Therapeutics, Inc. have?
Currently, no data Available
What happened to Iteos Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Iteos Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ITOS
Company Description
Iteos Therapeutics, Inc.
iTeos Therapeutics (ITOS) is a biotechnology company dedicated to the discovery and development of novel cancer immunotherapies. The company operates primarily in the pharmaceutical and biotechnology sectors, focusing on creating innovative treatments that harness the body's immune system to fight cancer. Its core products are centered around immuno-oncology drug candidates designed to target specific pathways involved in immune resistance and tumor growth.
Ownership Overview
―
Insiders
8.10%
Mutual Funds
― Other Institutional Investors
91.90% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---